GDRX
GoodRx Holdings, Inc.
GDRX's fundamentals are mixed, but it looks expensive: trading at 88x earnings, above its usual 66x. Analysts expect earnings growth, though they disagree widely on how much.
GDRX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
GDRX's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
GDRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $3.51 | — |
| Cheap | 35x | $1.38 | -61% |
| Fair | 65x | $2.60 | -26% |
| Current | 88x | $3.51 | — |
| Expensive | 213x | $8.51 | +142% |
Historical ranges are pointers, not guarantees.
GDRX's PE is in its fair range at 88x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
GDRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for GDRX, with profitability holding steady. However, they disagree widely on these estimates.
GDRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.35 | +778% |
| Q2 2026 | $0.04 | -56% |
| Q1 2026 | $0.06 | -14% |
| Q4 2025 | $0.09 | +125% |
| Q3 2025 | $0.08 | +$0.11 |
| Q2 2025 | $0.09 | +$0.22 |
| Q1 2025 | $0.07 | +$0.08 |
| Q4 2024 | $0.04 | +$0.06 |
| Q3 2024 | -$0.03 | -200% |
GDRX's earnings per share have fallen from their peak: $0.04 over the past year, against $0.20 in early 2020.
GDRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $200.4M | -1.3% |
| Q1 2026 | $194M | -4.4% |
| Q4 2025 | $194.8M | -1.9% |
| Q3 2025 | $196M | +0.4% |
| Q2 2025 | $203.1M | +1.2% |
| Q1 2025 | $203M | +2.6% |
| Q4 2024 | $198.6M | +1% |
| Q3 2024 | $195.3M | +8.5% |
GDRX's revenue grew through 2021 and has held roughly level since: $200M last quarter, down 1.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 12% | -1.4 points |
| Q1 2026 | 7.2% | -4.3 points |
| Q4 2025 | 12% | +2.5 points |
| Q3 2025 | 7.5% | -3 points |
| Q2 2025 | 13% | +3.3 points |
| Q1 2025 | 12% | +7.8 points |
| Q4 2024 | 9.2% | +19 points |
| Q3 2024 | 10% | +32 points |
GDRX's operating margin was 12% last quarter, down 1.4 points from the same quarter a year ago.
GDRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $80.5M | +64% |
| Q1 2026 | $10.7M | +15% |
| Q4 2025 | $31.6M | -29% |
| Q3 2025 | $74.3M | -14% |
| Q2 2025 | $49.2M | +421% |
| Q1 2025 | $9.3M | -78% |
| Q4 2024 | $44.6M | +188% |
| Q3 2024 | $86.5M | +44% |
GDRX's free cash flow has been positive every quarter for six years: $197M over the past year, up 4% from the year before.
GDRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +6.6M shares |
| 1 year | -2.5% | -9.1M shares |
| 3 years | -16% | -66.3M shares |
| 5 years | -19% | -80.8M shares |
| Available history | -4% | -14.5M shares |
GDRX has 348M diluted shares, down 2.5% from a year ago, with $85M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $2M |
| Q1 2026 | $12.6M |
| Q4 2025 | $9.4M |
| Q3 2025 | $61.1M |
| Q2 2025 | $46M |
| Q1 2025 | $99.9M |
| Q4 2024 | $188,000 |
| Q3 2024 | $5.4M |
GDRX spent $85M buying back its own shares over the past year, down 44% from the year before.
GDRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 0.3x | Very low |
| Q3 2024 | 0.6x | Very low |
GDRX's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GDRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.4 | Neutral |
| Stochastic | 50.9 | Neutral |
GDRX's weekly RSI is 58 (neutral) and its Stochastic is 51 (neutral).
GDRX PE vs Healthcare Sector
| Metric | GDRX | Sector median | Relative |
|---|---|---|---|
| PE | 88x | 26x | 239% above |
| PE % | 63 | 33 | 30 pts above |
GDRX is trading at 88x earnings, a 239% premium to the Healthcare sector's median of 26x.
GDRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.43 | 2.3% above |
| 20 week MA | $3.36 | 4.5% above |
| 50 week MA | $2.84 | 24% above |
| 100 week MA | $3.56 | 1.4% below |
| 200 week MA | $4.98 | 30% below |
GDRX has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 30% below its 200-week average.
GDRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $52.0 | $46.3 | -11% |
| 2021 | $46.3 | $33.6 | -28% |
| 2022 | $33.6 | $4.59 | -86% |
| 2023 | $4.59 | $6.70 | +46% |
| 2024 | $6.70 | $4.62 | -31% |
| 2025 | $4.62 | $2.75 | -40% |
| 2026 YTD | $2.75 | $3.51 | +28% |
GDRX has finished lower in five of the last six years. It's up 28% so far in 2026.